1.07 USD
▲+0.02+1.90%
盘后 1.16 0.00%
2026-09-16
市值
$3.85M
市盈率
—
EPS
-4.86
股息率
—
52 周区间
1.00 – 14.64
成交量
50.40K
Beta
1.83
目标价
14.00
52W 低 1.0052W 高 14.64
价格走势
公司简介
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatm...